Fig. 3.

Effect of LPC supplementation on hepatic VLDL production by Pla2g1b^−/− mice. The Pla2g1b^−/− mice (open symbols) were placed on hypercaloric diet for two weeks. (A) Fasting plasma triglyceride levels were measured after 11 h fasting (t = −1 h), and then LPC was injected intraperitoneally (32 mg/kg body weight). Poloxamer 407 was injected 1 h later at the 0 h time point, and plasma samples were obtained at hourly intervals thereafter to measure plasma triglyceride levels. (B) VLDL production rates of Pla2g1b^+/+ (filled bar) and Pla2g1b^−/− mice without (open bar) or with LPC injection (hatched bar). (C) Plasma triglyceride levels in Pla2g1b^+/+ (WT) and Pla2g1b^−/− (KO) mice with or without LPC injection measured before (filled bars) and 4 h after injection of Poloxamer 407 to inhibit lipolysis (open bars). Results represent mean ± SE from at least three mice in each group. Data were analyzed in comparison with Pla2g1b^+/+ mice as the control group by Student t-test *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001. ns, no significant difference.